2. GPCR/G Protein Neuronal Signaling
  3. Neurokinin Receptor
  4. Vofopitant

Vofopitant (GR 205171A) is a blood-brain barrier-permeable NK1 receptor inhibitor with a pKi of 9.02 in mice. Vofopitant blocks vomiting-related responses and inhibits pseudoptyalism. Vofopitant exerts anxiolytic effects, regulates 5-HT receptor function and increases central 5-HT release. Vofopitant improves hyperarousal symptoms of post-traumatic stress disorder. Vofopitant can be used in research related to depression, anxiety, vomiting and postoperative nausea and vomiting.

For research use only. We do not sell to patients.

Vofopitant

Vofopitant Chemical Structure

CAS No. : 168266-90-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Vofopitant:

Vofopitant Related Antibodies

Top Publications Citing Use of Products

View All Neurokinin Receptor Isoform Specific Products:

View All Isoforms
NK1R NK2R NK3R

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Vofopitant (GR 205171A) is a blood-brain barrier-permeable NK1 receptor inhibitor with a pKi of 9.02 in mice. Vofopitant blocks vomiting-related responses and inhibits pseudoptyalism. Vofopitant exerts anxiolytic effects, regulates 5-HT receptor function and increases central 5-HT release. Vofopitant improves hyperarousal symptoms of post-traumatic stress disorder. Vofopitant can be used in research related to depression, anxiety, vomiting and postoperative nausea and vomiting[1][2][3][4][5][6].

IC50 & Target

NK1R

9.02 (pKi)

Cellular Effect
Cell Line Type Value Description References
CHO IC50
0.08 nM
Compound: 3
Displacement of [125I]-labeled SP from the human Tachykinin receptor 1 expressed in CHO cells
Displacement of [125I]-labeled SP from the human Tachykinin receptor 1 expressed in CHO cells
[PMID: 9804700]
In Vitro

Vofopitant (GR 205171) (10 pM-1 mM; 60 min) potently inhibits [3H]-SP binding to NK1 receptors in mouse cerebral cortex homogenates with a pKi of 9.02[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vofopitant Related Antibodies
In Vivo

Vofopitant (GR 205171) (3-30 mg/kg; i.p.; single dose) produces a significant reduction in immobility time at the 30 mg/kg i.p. dose in the mouse forced swim test, with no corresponding change in frontal cortex extracellular monoamine levels[1].
Vofopitant (GR-205171) (50 µg/kg; i.v.; single dose) abolishes fictive retching and emesis-associated antral contractility enhancement, reduces emesis-related hypersalivation and parasympathetic nerve activity, but does not affect gastric corpus relaxation, vagosalivary reflex-mediated salivation, or linguosalivary reflex responses in dogs[2].
Vofopitant (GR 205171) (10 mg/kg; s.c.; single dose) does not alter DRN serotonergic neuron firing or 5-HT1A autoreceptor sensitivity in male C57BL/6J mice[4].
Vofopitant (10 mg/kg/day; s.c.; continuous delivery; 21 days) reduces the potency of Ipsapirone (HY-19686) to inhibit DRN serotonergic neuron firing by ~1.5-fold, indicating functional desensitization of 5-HT1A autoreceptors in male C57BL/6J mice[4].
Vofopitant (10 mg/kg/day; s.c.; continuous delivery; 21 days) reduces the potency and maximal effect of 5-CT to stimulate [35S]GTP-γ-S binding in the DRN, indicating impaired G-protein coupling of desensitized 5-HT1A autoreceptors in male C57BL/6J mice[4].
Vofopitant (10 mg/kg/day; s.c.; continuous delivery; 21 days) significantly increases basal extracellular 5-HT levels in the DRN and potentiates Paroxetine (HY-122272)-induced cortical 5-HT overflow in male C57BL/6J mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1 mice (20-26 g)[1]
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: i.p.; single dose
Result: Did not reduce immobility time obviously at 3 mg/kg.
Exerted mild and non-significant reduction at 10 mg/kg.
Reduced immobility time significantly at 30 mg/kg.
Showed no notable changes in cortical monoamine levels at 30 mg/kg within 300 minutes.
Animal Model: C57BL/6J (male, 8-10 weeks old, 20-25 g)[5]
Dosage: 10 mg/kg
Administration: s.c.; single dose
Result: Did not change firing frequency and pattern of DRN serotonergic neurons.
Exhibited comparable inhibitory potency of ipsapirone on neuronal firing between treatment and control groups.
Produced full inhibition at 100 nM ipsapirone in both groups.
Animal Model: C57BL/6J (male, 8-10 weeks old, 20-25 g)[5]
Dosage: 10 mg/kg/day
Administration: s.c.; continuous delivery; 21 days
Result: Did not change basal firing rate of DRN serotonergic neurons.
Decreased ipsapirone’s inhibitory potency on neuronal firing and raised its concentration for full inhibition.
Displayed similar basal [35S]GTP-γ-S labelling in the DRN between groups.
Weakened 5-CT-induced [35S]GTP-γ-S binding with a right-shifted curve and lower maximal response.
Exerted no influence on basal extracellular 5-HT in the frontal cortex but elevated basal 5-HT levels in the DRN.
Enhanced paroxetine-triggered 5-HT elevation in both cortex and DRN of treated mice.
Clinical Trial
Molecular Weight

432.44

Formula

C21H23F3N6O
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

COC1=C(CN[C@@H]2[C@H](C3=CC=CC=C3)NCCC2)C=C(N4C(C(F)(F)F)=NN=N4)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (231.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3125 mL 11.5623 mL 23.1246 mL
5 mM 0.4625 mL 2.3125 mL 4.6249 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.82%

SDS (252 KB)

COA (255 KB) HNMR (188 KB) LCMS (118 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3125 mL 11.5623 mL 23.1246 mL 57.8115 mL
5 mM 0.4625 mL 2.3125 mL 4.6249 mL 11.5623 mL
10 mM 0.2312 mL 1.1562 mL 2.3125 mL 5.7811 mL
15 mM 0.1542 mL 0.7708 mL 1.5416 mL 3.8541 mL
20 mM 0.1156 mL 0.5781 mL 1.1562 mL 2.8906 mL
25 mM 0.0925 mL 0.4625 mL 0.9250 mL 2.3125 mL
30 mM 0.0771 mL 0.3854 mL 0.7708 mL 1.9270 mL
40 mM 0.0578 mL 0.2891 mL 0.5781 mL 1.4453 mL
50 mM 0.0462 mL 0.2312 mL 0.4625 mL 1.1562 mL
60 mM 0.0385 mL 0.1927 mL 0.3854 mL 0.9635 mL
80 mM 0.0289 mL 0.1445 mL 0.2891 mL 0.7226 mL
100 mM 0.0231 mL 0.1156 mL 0.2312 mL 0.5781 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Vofopitant Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vofopitant168266-90-8GR 205171GR205171GR-205171Neurokinin ReceptorNK receptorTachykinin receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vofopitant
Cat. No.:
HY-12142
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.